Who is sponsoring NCT01638988?

NCT01638988 is sponsored by Clinique Ovo.

What condition does NCT01638988 study?

NCT01638988 studies Polycystic Ovary Syndrome, Insulin Resistance.

What drugs are being tested in NCT01638988?

Interventions: Metformin, Clomiphene citrate.

What is the status of NCT01638988?

NCT01638988 is currently WITHDRAWN.

Last reviewed 2015-07-24 · How we verify

Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome (PCOS) and a Resistance to Insulin. Randomised Controlled Study

NCT01638988 Phase 3 WITHDRAWN

The results of studies conducted until now does not determine what the best way to treat infertility in the first line with patients with Polycystic ovary syndrome (PCOS). This study objective is to determine the best treatment for such patients. The long-term consequence health of women with PCOS are multiple. The woman with PCOS has a risk of developing metabolic diseases, heart diseases, diabetes Type II or anovulatory infertility. The insulin resistance plays an important role in all this medical condition. Clomiphene Citrate (CC) remains the first line treatment to induce ovulation in women with PCOS and anovulatory infertility.

Details

Lead sponsor	Clinique Ovo
Phase	Phase 3
Status	WITHDRAWN
Start date	2013-09
Completion	2015-12

Conditions

Polycystic Ovary Syndrome
Insulin Resistance

Interventions

Metformin
Clomiphene citrate

Primary outcomes

Biochemical pregnancy — 1 month
Rate of biochemical pregnancy

Countries

Canada